Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients

20 Jun 2025

Abstract excerpt

Atypical hemolytic uremic syndrome (aHUS) is a rare and severe thrombotic microangiopathy caused by genetic or acquired abnormalities leading to activation of the complement alternative pathway on cell surfaces. This process leads to endothelial dysfunction and microvascular thrombosis. The introduction of anti-C5 antibodies has dramatically improved aHUS prognosis; however, these treatments require regular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Complement system in diseases
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40621468
DOI: 10.3389/fimmu.2025.1620996

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patientsPMID 40621468Read ↗

Overall Neutralization of Complement Factor H by Autoantibodies in the Acute Phase of the Autoimmune Form of Atypical Hemolytic Uremic SyndromeSemantic proximity Read ↗

aHUS caused by complement dysregulation: new therapies on the horizon.Semantic proximity Read ↗

Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panaceaSemantic proximity Read ↗

Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUSSemantic proximity Read ↗

A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.Semantic proximity Read ↗

Spectrum of Complement-Mediated Thrombotic Microangiopathies: Pathogenetic Insights Identifying Novel Treatment ApproachesSemantic proximity Read ↗

Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.Semantic proximity Read ↗

Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS seraSemantic proximity Read ↗

A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of functionSemantic proximity Read ↗

An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus documentSemantic proximity Read ↗

Factor H Autoantibodies and Complement-Mediated Diseases.Semantic proximity Read ↗

Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.